Baseline characteristics of patients
| . | All patients (n = 41) . | Aspirin only (n = 21) . | Aspirin plus etoricoxib (n = 20) . |
|---|---|---|---|
| Age (y) | 51 [43-63] | 55 [44-61] | 50.5 [41-64] |
| Males (n) | 21 | 12 | 9 |
| Time from diagnosis (y) | 1 [0.5-4] | 1.5 [0.5-4] | 1 [0.5-3] |
| History of vascular events (n) | MI (5), ischemic stroke (3), TIA (1), vein thrombosis (3) | MI (3), ischemic stroke (1), TIA (1), vein thrombosis (1) | MI (2), ischemic stroke (2), vein thrombosis (2) |
| Hydroxyurea (n) | 18 | 9 | 9 |
| JAK2 mutation (n)* | 23 | 12 | 11 |
| Platelet count at diagnosis (per μL) | 623 000 [536 500-788 000] | 640 000 [535 000-806 000] | 625 500 [581 000-778 000] |
| Platelet count at study entry (V0; per μL) | 444 000 [378 500-636 750] | 465 000 [396 000-606 000] | 426 500 [373 000-816 000] |
| Platelet count at V1 (per μL) | 439 500 [355 500-644,500] | 448 500 [377 000-577 000] | 399 000 [351 000-889 000] |
| Platelet count at V2 (per μL) | 458 500 [356 000-635 500] | 457 000 [375 000-559 000] | 458 500 [343 000-771 000] |
| Hemoglobin at study entry (mg/dL) | 14 [13.5-15] | 13.9 [13.5-15] | 14.3 [13.5-15.4] |
| Hematocrit at study entry (%) | 42.0 [40-44] | 42.3 [39.7-44.3] | 42.1 [40.2-44.5] |
| WBC at study entry (per μL) | 7080 [5475-8225] | 6910 [5110-7350] | 7275 [5950-8640] |
| MPV at study entry (fL) | 9.7 [9.3-10.2] | 10 [9.5-10.4] | 9.5 [9.1-9.7] |
| . | All patients (n = 41) . | Aspirin only (n = 21) . | Aspirin plus etoricoxib (n = 20) . |
|---|---|---|---|
| Age (y) | 51 [43-63] | 55 [44-61] | 50.5 [41-64] |
| Males (n) | 21 | 12 | 9 |
| Time from diagnosis (y) | 1 [0.5-4] | 1.5 [0.5-4] | 1 [0.5-3] |
| History of vascular events (n) | MI (5), ischemic stroke (3), TIA (1), vein thrombosis (3) | MI (3), ischemic stroke (1), TIA (1), vein thrombosis (1) | MI (2), ischemic stroke (2), vein thrombosis (2) |
| Hydroxyurea (n) | 18 | 9 | 9 |
| JAK2 mutation (n)* | 23 | 12 | 11 |
| Platelet count at diagnosis (per μL) | 623 000 [536 500-788 000] | 640 000 [535 000-806 000] | 625 500 [581 000-778 000] |
| Platelet count at study entry (V0; per μL) | 444 000 [378 500-636 750] | 465 000 [396 000-606 000] | 426 500 [373 000-816 000] |
| Platelet count at V1 (per μL) | 439 500 [355 500-644,500] | 448 500 [377 000-577 000] | 399 000 [351 000-889 000] |
| Platelet count at V2 (per μL) | 458 500 [356 000-635 500] | 457 000 [375 000-559 000] | 458 500 [343 000-771 000] |
| Hemoglobin at study entry (mg/dL) | 14 [13.5-15] | 13.9 [13.5-15] | 14.3 [13.5-15.4] |
| Hematocrit at study entry (%) | 42.0 [40-44] | 42.3 [39.7-44.3] | 42.1 [40.2-44.5] |
| WBC at study entry (per μL) | 7080 [5475-8225] | 6910 [5110-7350] | 7275 [5950-8640] |
| MPV at study entry (fL) | 9.7 [9.3-10.2] | 10 [9.5-10.4] | 9.5 [9.1-9.7] |
All values are expressed as medians [IQR] due to the skewed distribution of some variables.
MI indicates myocardial infarction; TIA, transient ischemic attack; WBC, white blood cells; and MPV, mean platelet volume.
JAK2 mutation screening was performed in 38 of 41 randomized patients, 20 in the etoricoxib arm and 18 in the aspirin-only arm.